病态肥胖患者肾活检病理谱的多病种分析
本研究基于哥伦比亚大学2017年3263例自体肾活检,筛选出248例BMI≥40 kg/m2的病态肥胖患者,中位年龄53.5岁,女性56%,中位BMI 44.0 kg/m2,糖尿病和高血压分别占47%和81%,中位eGFR 30 ml/min/1.73 m2,多数有肾病范围蛋白尿。肥胖相关肾小球病(ORG)73例(29例单纯ORG,44例ORG合并其他肾病),另167例为无ORG的其他肾病,以糖尿病肾病、急性肾小管坏死、高血压肾硬化、IgA肾病、膜性肾病和狼疮肾炎多见。49%的活检诊断预计会改变患者管理,非ORG病变最强预测因子为eGFR<30 ml/min/1.73 m2。
要点
- 病态肥胖患者肾活检病理谱广泛,ORG仅占部分,近半数诊断会改变管理。
- eGFR<30 ml/min/1.73 m2是非ORG病变最强预测因子。
- 非ORG病变较ORG更常表现为肾病综合征或急性肾损伤。
核心结论
- 病态肥胖患者肾脏病理远超代谢综合征相关病变,肾活检对指导管理和预后很重要。
研究设计与样本
- 回顾性分析哥伦比亚大学2017年3263例自体肾活检,纳入248例BMI≥40 kg/m2的病态肥胖患者。
主要发现
- 248例中位年龄53.5岁,女性56%,中位BMI 44.0 kg/m2,糖尿病47%,高血压81%,中位eGFR 30 ml/min/1.73 m2。
- ORG检出73例,其中单纯ORG 29例,ORG合并其他肾病44例;无ORG的其他肾病167例。
- 其他肾病最常见依次为糖尿病肾病、急性肾小管坏死、高血压肾硬化、IgA肾病、膜性肾病和狼疮肾炎。
- 49%的肾活检诊断预计会改变患者管理。
- 非ORG病变最强预测因子为eGFR<30 ml/min/1.73 m2,且更常表现为肾病综合征或急性肾损伤。
临床怎么用
- 病态肥胖伴肾病范围蛋白尿或肾功能下降者应积极考虑肾活检以明确病理诊断。
- eGFR<30 ml/min/1.73 m2或表现为肾病综合征/急性肾损伤时需警惕非ORG病变。
局限性
- 单中心回顾性研究,仅纳入2017年活检病例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Morbid obesity, defined as body mass index (BMI) ≥40 kg/m2, affects approximately 8% of United States adults and is a recognized risk factor for chronic kidney disease (CKD). We present the first focused biopsy-based study exploring the range of kidney diseases in this population. Among 3263 native kidney biopsies interpreted at Columbia University in 2017, we identified 248 biopsies from morbidly obese patients. In this cohort with median age of 53.5 years, 56% were female and median BMI was 44.0 kg/m2. Diabetes and hypertension were present in 47% and 81% of patients, respectively. Median estimated glomerular filtration rate (eGFR) was 30 ml/min/1.73 m2, and most patients had nephrotic range proteinuria. Obesity related glomerulopathy (ORG), defined as focal segmental glomerulosclerosis with glomerulomegaly or glomerulomegaly alone, was detected in 73 patients, including 29 with ORG alone and 44 with ORG plus another kidney disease. In contrast, 167 patients had other kidney diseases alone, without ORG, most commonly (in descending order) diabetic nephropathy, acute tubular necrosis, hypertensive nephrosclerosis, IgA nephropathy, membranous nephropathy, and lupus nephritis. In 49% of patients, kidney biopsy yielded a diagnosis predicted to change patient management. The strongest predictor of non-ORG lesions was eGFR <30 ml/min per 1.73 m2, and presentation with nephrotic syndrome or acute kidney injury (with or without background CKD) was more common in non-ORG than ORG. The findings reveal an unexpectedly broad spectrum of kidney pathology beyond metabolic syndrome-associated disorders and highlight the importance of kidney biopsy to guide management and prognosis in the morbidly obese population.
引用
- Choung HG, Bomback AS, Stokes MB, et al. The spectrum of kidney biopsy findings in patients with morbid obesity. Kidney Int. 2019. PMID: 30712921. doi:10.1016/j.kint.2018.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。